These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 28734620

  • 1. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J.
    J Vet Cardiol; 2017 Aug; 19(4):325-338. PubMed ID: 28734620
    [Abstract] [Full Text] [Related]

  • 2. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 3. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Feb; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 4. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q, Heaney A, Langenfeld-McCoy N, Boler BV, Laflamme DP.
    BMC Vet Res; 2019 Nov 27; 15(1):425. PubMed ID: 31775756
    [Abstract] [Full Text] [Related]

  • 5. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov 27; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 6. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 27; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 7. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 27; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 8. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M, Hori Y, Kanno N, Iwasa N, Toyofuku T, Isayama N, Yoshikawa A, Akabane R, Sakatani A, Miyakawa H, Hsu HH, Miyagawa Y, Takemura N.
    J Vet Med Sci; 2021 Apr 24; 83(4):705-715. PubMed ID: 33551383
    [Abstract] [Full Text] [Related]

  • 9. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K, Riengvirodkij N, Channgam P, Kaenchan P, Buayam W, Janhirun Y, Phonarknguen R, Tansakul M, Sakcamduang W.
    Open Vet J; 2024 Jun 24; 14(6):1426-1441. PubMed ID: 39055758
    [Abstract] [Full Text] [Related]

  • 10. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS, Yoon WK, Choi EW.
    Ir Vet J; 2023 Feb 08; 76(1):3. PubMed ID: 36755290
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Feb 08; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 12. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL, Visser LC, Gunther-Harrington CT, Ontiveros ES, Wittenburg LA, Palm CA, Stern JA.
    J Vet Intern Med; 2022 Nov 08; 36(6):1892-1899. PubMed ID: 36098206
    [Abstract] [Full Text] [Related]

  • 13. Left atrial volume and function in dogs with naturally occurring myxomatous mitral valve disease.
    Höllmer M, Willesen JL, Tolver A, Koch J.
    J Vet Cardiol; 2017 Feb 08; 19(1):24-34. PubMed ID: 27825670
    [Abstract] [Full Text] [Related]

  • 14. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A, Bagardi M, Stranieri A, Zanaboni AM, Malchiodi D, Borromeo V, Brambilla PG, Locatelli C.
    BMC Vet Res; 2021 Jan 07; 17(1):15. PubMed ID: 33413406
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory and immune variables as predictors of survival in dogs with myxomatous mitral valve disease.
    Cimerman M, Druzhaeva N, Nemec Svete A, Hajdinjak M, Pohar K, Ihan A, Domanjko Petrič A.
    BMC Vet Res; 2024 Sep 28; 20(1):431. PubMed ID: 39342325
    [Abstract] [Full Text] [Related]

  • 16. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun 28; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 18. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ, Ljungvall I, Hillström A, Møller JE, Hagman R, Falk T, Höglund K, Häggström J, Olsen LH.
    Vet J; 2016 Mar 23; 209():113-8. PubMed ID: 26831162
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010 Mar 23; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 20. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 23; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.